Drug Profile
Tamnorzatinib - Ono Pharmaceutical
Alternative Names: ONO 7475Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Developer Ono Pharmaceutical; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia
- Phase I/II Myelodysplastic syndromes
- Phase I Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 15 Feb 2024 Phase-I clinical trials in Pancreatic cancer in Japan (PO) before February 2024 (Ono Pharmaceutical pipeline, February 2024)
- 15 Jun 2023 Tamnorzatinib is still in phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Combination therapy, Monotherapy) in Japan (PO, Tablet)
- 28 Jan 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Japan (PO, Tablet)